SSTR2 and breast carcinoma: Diagnostic SPECT and scintigraphy with 111In-pentatreotide and 99mTc-depreotide, have been explored clinically in patients with sstr2-positive breast cancer (Alberini et al. 2000; van Eijck et al. 1994; Wang et al. 2008).